Infliximab for Crohn's disease: The first 500 patients followed up through 2009

Digestive Diseases and Sciences

Volumn 58, Issue 3, 2013, Pages 797-806

  Seminerio, Jennifer L ^a   Loftus Jr , Edward V ^a   Colombel, Jean Frédéric ^b   Thapa, Prabin ^a   Sandborn, William J ^a,c  

^a MAYO CLINIC   (United States)

^b UNIV LILLE   (France)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adverse events; Crohn's disease; Infections; Infliximab; Malignancy; Mortality

Indexed keywords

AZATHIOPRINE; BUDESONIDE; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; TACROLIMUS;

ABSCESS; ADOLESCENT; ADULT; AGED; ARTICLE; BACTERIAL INFECTION; CANDIDIASIS; CHILD; CLINICAL PRACTICE; CLOSTRIDIUM DIFFICILE INFECTION; CROHN DISEASE; DELAYED HYPERSENSITIVITY; DRUG DOSE ESCALATION; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; ESCHERICHIA COLI INFECTION; FEMALE; FOLLOW UP; HEPATITIS; HERPES SIMPLEX; HISTOPLASMOSIS; HUMAN; INFECTION; INFUSION; INFUSION RELATED REACTION; LEUKEMIA; LONG TERM CARE; LYMPHOMA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MYCOBACTERIOSIS; MYCOSIS; NON MELANOMA SKIN CANCER; PNEUMONIA; PRESCHOOL CHILD; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; SCHOOL CHILD; SEPTIC SHOCK; SEPTICEMIA; SOLID TUMOR; SURVIVAL RATE; TREATMENT RESPONSE; TUBERCULOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; BACTERIAL INFECTIONS; CHILD; CHILD, PRESCHOOL; CROHN DISEASE; DRUG HYPERSENSITIVITY; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL AGENTS; HUMANS; MALE; MIDDLE AGED; MYCOSES; NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 84876693416     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-012-2405-z     Document Type: Article

References (21)

1. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007;369:1641-1657.
2. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's disease cA2 study group. N Engl J Med. 1997;337:1029-1035.
3. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999;340:1398-1405.
4. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359:1541-1549.
5. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004;350:876-885.
6. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha- neutralizing agent. N Engl J Med. 2001;345:1098-1104.
7. Lee JH, Slifman NR, Gershon SK, et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum. 2002;46:2565-2570.
8. Brown SL, Greene MH, Gershon SK, et al. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the food and drug administration. Arthritis Rheum. 2002;46:3151-3158.
9. Siegel CA, Marden SM, Persing SM, et al. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol. 2009;7:874-881.
10. Mackey AC, Green L, Liang LC, et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007;44:265-267.
11. Farrell RJ, Shah SA, Lodhavia PJ, et al. Clinical experience with infliximab therapy in 100 patients with Crohn's disease. Am J Gastroenterol. 2000;95:3490-3497.
12. Cohen RD, Tsang JF, Hanauer SB. Infliximab in Crohn's disease: first anniversary clinical experience. Am J Gastroenterol. 2000;95:3469-3477.
13. Ricart E, Panaccione R, Loftus EV, et al. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients. Am J Gastroenterol. 2001;96:722-729.
14. Arnott ID, McDonald D, Williams A, et al. Clinical use of infliximab in Crohn's disease: the Edinburgh experience. Aliment Pharmacol Ther. 2001;15:1639-1646.
15. Hommes DW, van de Heisteeg BH, van der Spek M, et al. Infliximab treatment for Crohn's disease: one-year experience in a Dutch academic hospital. Inflamm Bowel Dis. 2002;8:81-86.
16. Sample C, Bailey RJ, Todoruk D, et al. Clinical experience with infliximab for Crohn's disease: the first 100 patients in Edmonton, Alberta. Can J Gastroenterol. 2002;16:165-170.
17. Colombel JF, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology. 2004;126:19-31.
18. Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut. 2009;58:492-500.
19. Fidder H, Schnitzler F, Ferrante M, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut. 2009;58:501-508.
20. Cottone M, Kohn A, Daperno M, et al. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9:30-35.
21. Biancone L, Petruzziello C, Orlando A, et al. Cancer in Crohn's disease patients treated with infliximab: a long-term multicenter matched pair study. Inflamm Bowel Dis. 2011;17:758-766.